Obinutuzumab (Gazyvaro®) for Lymphocytic Leukaemia

Assessment Status Assessment process complete
Drug Obinutuzumab
Brand Gazyvaro®
Indication In combination with chlorambucil for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia and with comorbidities making them unsuitable for full-dose fludarabine based therapy.
Assessment Process
Rapid review commissioned 08/08/2014
Rapid review completed 11/09/2014
Rapid review outcome Full Pharmacoeconomic Assessment Recommended
Full pharmacoeconomic assessment commissioned by HSE 30/09/2014
NCPE assessment completed 02/04/2015
NCPE assessment outcome Reimbursement not recommended.

Technical Summary

December 2015

The HSE has approved reimbursement following confidential price negotiations.